TPIAT stands for total pancreatectomy with islet autotransplantation. It’s a major surgery that removes the entire pancreas to eliminate chronic pain, then rescues the insulin-producing cells (called islets) from the removed organ and infuses them into the liver, where they can continue making insulin. The goal is twofold: stop the source of debilitating pain and preserve as much of the body’s ability to regulate blood sugar as possible.
Who Is a Candidate for TPIAT
TPIAT is reserved for people with chronic pancreatitis or recurrent acute pancreatitis whose pain has not responded to other treatments. That includes medications, endoscopic procedures, and prior surgeries. The pain must be severe enough to seriously impair quality of life, whether that means repeated hospitalizations, constant need for narcotic pain medications, or inability to work or attend school.
Before being considered, you need objective evidence that pancreatitis is actually the diagnosis and that the pain originates from the pancreas. This is typically confirmed through some combination of imaging (CT, MRI, or endoscopic ultrasound), pancreatic function testing, tissue samples from prior surgeries, or documented genetic mutations linked to hereditary pancreatitis, such as PRSS1, SPINK1, or CFTR gene mutations.
People with hereditary pancreatitis receive special consideration because their disease is unlikely to go away on its own and carries a higher lifetime risk of pancreatic cancer. Many specialists advocate for earlier surgery in these patients, particularly children, to prevent progressive destruction of islet cells while also reducing cancer risk. TPIAT is not recommended for self-limited disease like a single episode of severe acute pancreatitis.
How the Surgery Works
The operation has three distinct phases: removing the pancreas, processing the organ in a laboratory, and transplanting the islet cells back into the body.
Removing the Pancreas
The pancreatectomy is performed in two stages through an open abdominal incision. First, surgeons remove the body and tail of the pancreas (with or without the spleen). Then they remove the head of the pancreas along with the duodenum, the first section of the small intestine. To protect the islet cells from damage, blood supply to the pancreas is preserved as long as possible before the organ is actually taken out. The spleen can sometimes be saved by maintaining its connection to other blood vessels.
Isolating the Islet Cells
Once the pancreas is removed, it’s immediately placed in cold preservation solution and rushed to an isolation laboratory, often in the same hospital. The goal is to separate the insulin-producing islet cells from the rest of the pancreatic tissue. Technicians inject a digestive enzyme called collagenase through the pancreatic duct, which breaks down the surrounding tissue and frees the islets. The resulting material is then assessed for the number of viable islets, their purity, and safety.
The number of islets recovered matters enormously. Islet yield is measured in “islet equivalents per kilogram of body weight” (IEQ/kg). Patients who receive more than 5,000 IEQ/kg have a high chance of remaining insulin-independent after surgery. Those receiving at least 2,500 IEQ/kg generally maintain partial islet function, meaning they still produce some insulin even if they need supplemental doses. In chronic pancreatitis, the pancreas is often so damaged and scarred that the tissue volume is relatively small, which can limit how many islets are recoverable.
Transplanting Islets Into the Liver
The isolated islets are infused into the portal vein, the large blood vessel that carries blood into the liver. A catheter is placed either during the open surgery or through the skin under imaging guidance. The islets flow with the blood into progressively smaller branches of the portal vein, where they become physically trapped. Larger islets lodge in small portal vein branches, while smaller ones can reach the tiny blood vessels called sinusoids within the liver tissue itself. Over time, roughly half of the transplanted islets attach to the walls of these blood vessels and establish a new blood supply, effectively setting up a new home where they can sense blood sugar and release insulin.
Recovery and Life After Surgery
TPIAT is a long operation, and recovery typically involves a hospital stay of several weeks. Because the entire pancreas has been removed, two permanent changes affect daily life: you will no longer produce digestive enzymes, and your ability to make insulin depends entirely on how well the transplanted islets function.
Pancreatic enzyme replacement is mandatory for every patient after surgery. These are capsules containing lipase, amylase, and other digestive enzymes in coated microspheres designed to release in the intestine. You take them with every meal and every snack. The typical dosing range is 500 to 2,000 lipase units per kilogram of body weight per meal. Finding the right dose is a process of clinical adjustment. In adults, adequate dosing is judged by the ability to maintain a healthy weight. In children, weight gain and growth are the key markers. Fat-soluble vitamin levels are also monitored to catch subtle malabsorption. Some patients benefit from adding an acid-suppressing medication to help the enzymes work more effectively.
Digestive symptoms like bloating, diarrhea, or abdominal discomfort can persist even with proper enzyme dosing. When that happens, doctors may investigate other causes such as small intestinal bacterial overgrowth, celiac disease, or other absorptive conditions.
Pain Relief Outcomes
Pain relief is the primary reason for TPIAT, and the results are generally strong. In a large pediatric study, 90% of children experienced statistically significant improvement in pancreatitis pain after surgery. Among adults, 55% were free of narcotic pain medications at one year, and that number climbed to 73% at five years, suggesting that pain relief continues to improve over time rather than fading.
Diabetes Risk After TPIAT
Since the pancreas is completely removed, the risk of developing diabetes depends on how many islet cells survive the isolation and transplantation process. Most patients need insulin immediately after surgery while the islets settle into the liver and begin functioning. About 55% of patients are insulin-independent by one year. In a pediatric cohort, all patients maintained blood sugar control below diabetic thresholds at one year, even those who still required some insulin.
Several factors predict who is most likely to stay off insulin: younger age, higher islet yield (the single strongest predictor), smaller body size, and not having had certain prior pancreatic surgeries. In children, a study of 75 patients found that 41% achieved full insulin independence. Those who did require insulin often needed relatively low doses, ranging from 0.06 to 0.71 units per kilogram per day, far less than typical type 1 diabetes management. Even partial islet function is valuable because it helps stabilize blood sugar, reduces insulin requirements, and lowers the risk of dangerous low blood sugar episodes.
Surgical Risks and Complications
TPIAT is a major operation with the risk of significant blood loss. The most specific complication is portal vein thrombosis, a blood clot forming in the vein used for islet infusion. In a large series at the University of Minnesota spanning nearly two decades, 6.6% of patients developed this complication. The good news is that 83% of those clots resolved within six months with blood-thinning treatment. Most clots occurred in side branches rather than the main portal vein, limiting their severity.
Other potential complications include those common to any major abdominal surgery: infection, bleeding requiring transfusion, and blood clots elsewhere in the body such as deep vein thrombosis or pulmonary embolism. Blood-thinning medications are given after surgery to reduce clotting risk, though finding the right balance between preventing clots and avoiding bleeding requires careful monitoring.
TPIAT in Children
Children with hereditary pancreatitis are increasingly recognized as strong candidates for TPIAT. Their disease tends to be progressive, meaning the pancreas sustains ongoing damage that destroys islet cells over time. Operating earlier, before the pancreas is severely scarred, can preserve more islets and improve the chances of insulin independence. Younger age and smaller body size are both associated with better islet outcomes, which gives children a meaningful advantage.
Qualifying criteria for children mirror those for adults: pain lasting more than six months, impaired quality of life (missing school, repeated hospitalizations, inability to participate in normal activities), and failure of medical or endoscopic treatment. The long-term data in children shows durable pain relief and quality-of-life improvements, making TPIAT one of the few interventions that can fundamentally change the trajectory of hereditary pancreatitis when caught early enough.